The exact role of engineered nanomaterials in immune system modulation remains unclear. The aim of this concise review is to give a comprehensive insight into recent published scientific data concerning the modulation of innate and adaptive immune responses by engineered nanoparticles, and to provide a basis for future experimental work related to designing safer, and more efficient biomaterials.
PanticI. (2010) Magnetic nanoparticles in cancer diagnosis and treatment: novel approaches. Rev. Adv. Mater. Sci., 26, 14–34.
2.
PowellA.C., PaciottiG.F., and LibuttiS.K. (2010) Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol. Biol., 624, 375–384.
3.
ZolnikB.S., and SadriehN. (2009) Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv. Drug Deliv. Rev., 61, 422–427.
4.
PetrelliF., BorgonovoK., and BarniS. (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin. Pharmacother., 11, 1413–1432.
5.
DobrovolskaiaM.A., and McNeilS.E. (2007) Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2, 469–478.
6.
StolnikS., IllumL., and DavisS.S. (1995) Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev., 16, 195.
7.
ShanX., LiuC., YuanY., XuF., TaoX., ShengY., and ZhouH. (2009) In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer. Colloids Surf. B. Biointerfaces, 72, 303–311.
8.
RyanS.M., MantovaniG., WangX., HaddletonD.M., and BraydenD.J. (2008) Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv., 5, 371–383.
9.
OwensD.E.3rd, and PeppasN.A. (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 307, 93–102.
10.
GonçalvesC., TorradoE., MartinsT., PereiraP., PedrosaJ., and GamaM. (2010) Dextrin nanoparticles: studies on the interaction with murine macrophages and blood clearance. Colloids Surf. B. Biointerfaces, 75(2), 483–489.
11.
ZhangY., KohlerN., and ZhangM. (2002) Surface modification of super-paramagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 23, 1553–1561.
12.
ZhangZ., JiaJ., LaiY., MaY., WengJ., and SunL. (2010) Conjugating folic acid to gold nanoparticles through glutathione for targeting and detecting cancer cells. Bioorg. Med. Chem., 18, 5528–5534.
13.
PanJ., and FengS.S. (2009) Targeting and imaging cancer cells by folatedecorated, quantum dots (QDs)–loaded nanoparticles of biodegradable polymers. Biomaterials, 30, 1176–1183.
14.
ZhengY., CaiZ., SongX., ChenQ., BiY., LiY., and HouS. (2009) Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies. J. Drug Target, 17, 294–303.
15.
SantraS., LiesenfeldB., DuttaD., ChatelD., BatichC.D., TanW., MoudgilB.M., and MericleR.A. (2005) Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J. Nanosci. Nanotechnol., 5, 899–904.
SinghM., ChakrapaniA., and O'HaganD. (2007) Nanoparticles and micro-particles as vaccine-delivery systems. Expert Rev. Vaccines, 6, 797–808.
21.
PoddaA., Del GiudiceG., and O'HaganD.T. (2006) MF59: a safe and potent adjuvant for human use. In: SchijnsV.E.J.C., and O'HaganD.T. (eds.), Immunopotentiators in modern vaccines, pp. 149–159. Academic Press, Burlington, MA.
22.
DraneD., and PearseM.J. (2006) The ISCOMATRIXTM adjuvant. In: SchijnsV.E.J.C., and O'HaganD.T. (eds.), Immunopotentiators in modern vaccines, pp. 191–215. Academic Press, Burlington, MA.
23.
KabanovA.V., and VinogradovS.V. (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew. Chem. Int. Ed. Engl., 48, 5418–5429.
24.
OishiM., and NagasakiY. (2010) Stimuli-responsive smart nanogels for cancer diagnostics and therapy. Nanomedicine (Lond.), 5, 451–468.
25.
KitanoS., KageyamaS., NagataY., MiyaharaY., HiasaA., NaotaH., OkumuraS., ImaiH., ShiraishiT., MasuyaM., NishikawaM., SunamotoJ., AkiyoshiK., KanematsuT., ScottA.M., MurphyR., HoffmanE.W., OldL.J., and ShikuH. (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin. Cancer Res., 12, 7397–7405.
26.
KageyamaS., KitanoS., HirayamaM., NagataY., ImaiH., ShiraishiT., AkiyoshiK., ScottA.M., MurphyR., HoffmanE.W., OldL.J., KatayamaN., and ShikuH. (2008) Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci., 99, 601–607.
27.
AokiM., UedaS., NishikawaH., KitanoS., HirayamaM., IkedaH., ToyodaH., TanakaK., KanaiM., TakabayashiA., ImaiH., ShiraishiT., SatoE., WadaH., NakayamaE., TakeiY., KatayamaN., ShikuH., and KageyamaS. (2009) Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, 27, 6854–6861.
28.
KawabataR., WadaH., IsobeM., SaikaT., SatoS., UenakaA., MiyataH., YasudaT., DokiY., NoguchiY., KumonH., TsujiK., IwatsukiK., ShikuH., RitterG., MurphyR., HoffmanE., OldL.J., MondenM., and NakayamaE. (2007) Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int. J. Cancer, 120, 2178–2184.
29.
YoshikawaT., OkadaN., OdaA., MatsuoK., MatsuoK., MukaiY., YoshiokaY., AkagiT., AkashiM., and NakagawaS. (2008) Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Biochem. Biophys. Res. Commun., 366(2), 408–413.
30.
YamaguchiS., TatsumiT., TakeharaT., SasakawaA., YamamotoM., KohgaK., MiyagiT., KantoT., HiramastuN., AkagiT., AkashiM., and HayashiN. (2010) EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol Immunother., 59(5), 759–767.
31.
NakagawaS. (2008) Efficacy and safety of poly (gamma-glutamic acid) based nanoparticles (gamma-PGA NPs) as vaccine carrier. Yakugaku Zasshi., 128(11), 1559–1565.
32.
BroosS., LundbergK., AkagiT., KadowakiK., AkashiM., GreiffL., BorrebaeckC.A., and LindstedtM. (2010) Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: Implications for specific immunotherapy. Vaccine, 28(31), 5075–5085.
33.
VallhovH., QinJ., JohanssonS.M., AhlborgN., MuhammedM.A., ScheyniusA., and GabrielssonS. (2006) The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett., 6(8), 1682–1686.
34.
JonesC.F., and GraingerD.W. (2009) In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev., 61(6), 438–456.
35.
GordonE.M., LevyJ.P., ReedR.A., PetchpudW.N., LiuL., WendlerC.B., and HallF.L. (2008) Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int. J. Oncol., 33, 665–675.
36.
ChakravarthyK.V., BonoiuA.C., DavisW.G., RanjanP., DingH., HuR., BowzardJ.B., BergeyE.J., KatzJ.M., KnightP.R., SambharaS., and PrasadP.N. (2010) Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc. Natl. Acad. Sci. USA, 107, 10172–10177.
37.
NguyenD.N., ChenS.C., LuJ., GoldbergM., KimP., SpragueA., NovobrantsevaT., ShermanJ., Shulga-MorskayaS., de FougerollesA., ChenJ., LangerR., and AndersonD.G. (2009) Drug delivery-mediated control of RNA immunostimulation. Mol. Ther., 17, 1555–1562.
38.
SubramanyaS., KimS.S., AbrahamS., YaoJ., KumarM., KumarP., HaridasV., LeeS.K., ShultzL.D., GreinerD.N.M., and ShankarP. (2010) Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J. Virol., 84, 2490–2501.
39.
DobrovolskaiaM.A., GermolecD.R., and WeaverJ.L. (2009) Evaluation of nanoparticle immunotoxicity. Nature Nanotechnol., 4, 411–414.
40.
LadicsG.S. (2007) Primary immune response to sheep red blood cells (SRBC) as the conventional T-cell dependent antibody response (TDAR) test. J. Immunotoxicol., 4, 149–52.
41.
TurjacaninD., PanticI., and RisticS. (2009) Effects of prolonged administration of lysine-acetylsalicylate on humoral immune response in guinea-pigs. Second congress of physiological sciences of Serbia with international participation, p. 147. Kragujevac, Serbia, Abstract Book.
42.
KedmiR., Ben-ArieN., and PeerD. (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 31, 6867–6875.
43.
SchanenB.C., KarakotiA.S., SealS., DrakeD.R.3rd, WarrenW.L., and SelfW.T. (2009) Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct. ACS Nano, 3, 2523–2532.
44.
AinslieK.M., TaoS.L., PopatK.C., DanielsH., HardevV., GrimesC.A., and DesaiT.A. (2009) In vitro inflammatory response of nanostructured titania, silicon oxide, and polycaprolactone. J. Biomed. Mater. Res. A, 91, 647–655.
